Background There seems to be a clear correlation between antibodies against domain I
(anti-DI) of β2Glycoprotein I and severe clinical profiles in antiphospholipid syndrome (APS) …

Abstract Background IgG anti-Domain I (anti-DI) β2 Glycoprotein I (β2GPI) antibodies are
associated to thrombotic risk in antiphospholipid syndrome (APS), but their detection is …

Background Antiphospholipid syndrome (APS) is characterized by the presence of
circulating antiphospholipid antibodies (aPL) in patients with thrombosis and/or pregnancy …

Essentials• Antibodies to domain 1 of β 2 glycoprotein I (aD1) are a subset of
antiphospholipid antibodies.• We evaluated the added diagnostic value of an automated …

As the clinical symptoms of the antiphospholipid syndrome (APS) frequently occur
irrespective of the syndrome, diagnosis predominantly depends on the laboratory assays …

Abstract Beta-2 glycoprotein I (β 2 GPI) is the main antigenic target for antiphospholipid
antibodies (aPL), the serological markers of antiphospholipid syndrome (APS). Domain I (DI) …

In 1990, b2-glycoprotein I (b2-GPI) was shown to be the main protein cofactor involved in the
binding of antiphospholipid antibodies to anionic phospholipids [1–3]. The presence of b2 …

Objective. The objective of this study was to extend the findings of the preliminary study by
measuring the avidity of IgG anti-β2-glycoprotein I antibodies (anti-β2-GPI) on a larger group …

Antibodies against β2-glycoprotein I (anti-β2GPI) are one of the hallmarks of the
antiphospholipid syndrome (APS). However, they are heterogenic regarding their epitope …

To investigate the prevalence, significance, and specificity of IgG isotype anti-β2-
Glycoprotein I antibodies (a-β2-GPI) in antiphospholipid syndrome (APS), we developed an …